EP2195003A4 - COMBINATION THERAPY AGAINST PANCREATIC CANCER WITH AN ANTIGEN PEPTIDE AND CHEMOTHERAPEUTIC - Google Patents

COMBINATION THERAPY AGAINST PANCREATIC CANCER WITH AN ANTIGEN PEPTIDE AND CHEMOTHERAPEUTIC

Info

Publication number
EP2195003A4
EP2195003A4 EP08828542A EP08828542A EP2195003A4 EP 2195003 A4 EP2195003 A4 EP 2195003A4 EP 08828542 A EP08828542 A EP 08828542A EP 08828542 A EP08828542 A EP 08828542A EP 2195003 A4 EP2195003 A4 EP 2195003A4
Authority
EP
European Patent Office
Prior art keywords
pancreatic cancer
combination therapy
chemotherapeutic agent
antigenic peptide
antigenic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP08828542A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP2195003A1 (en
Inventor
Hiroki Yamaue
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncotherapy Science Inc
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of EP2195003A1 publication Critical patent/EP2195003A1/en
Publication of EP2195003A4 publication Critical patent/EP2195003A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/852—Pancreas

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
EP08828542A 2007-08-24 2008-08-19 COMBINATION THERAPY AGAINST PANCREATIC CANCER WITH AN ANTIGEN PEPTIDE AND CHEMOTHERAPEUTIC Withdrawn EP2195003A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95792307P 2007-08-24 2007-08-24
PCT/JP2008/002232 WO2009028150A1 (en) 2007-08-24 2008-08-19 Combination therapy for pancreatic cancer using an antigenic peptide and chemotherapeutic agent

Publications (2)

Publication Number Publication Date
EP2195003A1 EP2195003A1 (en) 2010-06-16
EP2195003A4 true EP2195003A4 (en) 2011-07-06

Family

ID=40386893

Family Applications (1)

Application Number Title Priority Date Filing Date
EP08828542A Withdrawn EP2195003A4 (en) 2007-08-24 2008-08-19 COMBINATION THERAPY AGAINST PANCREATIC CANCER WITH AN ANTIGEN PEPTIDE AND CHEMOTHERAPEUTIC

Country Status (19)

Country Link
US (1) US8703713B2 (ru)
EP (1) EP2195003A4 (ru)
JP (1) JP5417667B2 (ru)
KR (1) KR20100047899A (ru)
CN (1) CN101883577A (ru)
AR (1) AR068020A1 (ru)
AU (1) AU2008292966C1 (ru)
BR (1) BRPI0815726A2 (ru)
CA (1) CA2697501A1 (ru)
IL (1) IL204143A (ru)
MX (1) MX2010002178A (ru)
MY (1) MY160406A (ru)
NZ (1) NZ583578A (ru)
RU (1) RU2472522C2 (ru)
SG (1) SG183770A1 (ru)
TW (1) TWI436775B (ru)
UA (1) UA100702C2 (ru)
WO (1) WO2009028150A1 (ru)
ZA (1) ZA201001580B (ru)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2267023B1 (en) 2002-09-12 2015-02-11 Oncotherapy Science, Inc. KDR peptides and vaccines comprising the same
US20080034017A1 (en) * 2006-08-04 2008-02-07 Dominic Giampaolo Links to a common item in a data structure
TW201109029A (en) 2009-06-11 2011-03-16 Oncotherapy Science Inc Vaccine therapy for choroidal neovascularization
JP5904552B2 (ja) * 2010-05-28 2016-04-13 国立研究開発法人国立がん研究センター 膵癌治療剤
DE102013214023B4 (de) * 2013-07-17 2015-02-12 Siemens Aktiengesellschaft Verfahren zu einem Auswerten und Vergleichen von zeitlich aufeinander folgenden kombinierten medizinischen Bildgebungsuntersuchungen sowie ein medizinisches Bildgebungssystem, das zu einem Ausführen des erfindungsgemäßen Verfahrens ausgelegt ist
PT3205720T (pt) * 2014-10-09 2019-10-28 Univ Yamaguchi Vetor de expressão de car e células t que expressam car
CN107106638A (zh) * 2014-10-14 2017-08-29 激流生物科学有限公司 具有抗炎特性的肽
WO2018212358A1 (ja) * 2017-05-19 2018-11-22 学校法人慶應義塾 脳神経疾患に対するペプチドワクチン及びペプチドワクチン組成物
US10413584B1 (en) 2018-08-29 2019-09-17 Riptide Bioscience, Inc. Peptides having immunomodulatory properties
US10548944B1 (en) 2018-10-19 2020-02-04 Riptide Bioscience, Inc. Antimicrobial peptides and methods of using the same

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060216301A1 (en) * 2002-09-12 2006-09-28 Oncotherapy Science, Inc. Kdr peptides and vaccines containing the same

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB213645A (en) 1922-12-22 1924-03-24 Frank Lincoln Morse Improvements in and relating to chain and sprocket wheel gearing
US3265572A (en) 1961-09-20 1966-08-09 S B Penick And Company Process for preparing tyrociding and product produced thereby
US4526988A (en) 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
DK0694042T3 (da) 1993-03-25 2005-02-14 Merck & Co Inc Inhibitor af vaskulær endothelcellevækstfaktor
US6080728A (en) 1996-07-16 2000-06-27 Mixson; A. James Carrier: DNA complexes containing DNA encoding anti-angiogenic peptides and their use in gene therapy
DE19638745C2 (de) 1996-09-11 2001-05-10 Schering Ag Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR)
US6348333B1 (en) 1997-01-17 2002-02-19 Toa Gosei Co., Ltd. VEGF-binding KDR polypeptide
WO1999040118A1 (fr) 1998-02-04 1999-08-12 Kyowa Hakko Kogyo Co., Ltd. Anticorps diriges contre le recepteur kdr humain du vegf
GB9804121D0 (en) 1998-02-26 1998-04-22 Cancer Res Campaign Tech Anti-angiogenic vaccines: materials and methods relating thereto
EP1086705A4 (en) 1998-05-20 2002-02-06 Kyowa Hakko Kogyo Kk INHIBITORS OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) ACTIVITY
US7087411B2 (en) * 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US7320793B2 (en) 2001-01-19 2008-01-22 Cytos Biotechnology Ag Molecular antigen array
CU23178A1 (es) * 2002-04-15 2006-09-22 Ct Ingenieria Genetica Biotech INMUNOTERAPIA ACTIVA ANTIANGIOGéNICA
US7265096B2 (en) 2002-11-04 2007-09-04 Xenoport, Inc. Gemcitabine prodrugs, pharmaceutical compositions and uses thereof
DE602005027673D1 (de) * 2004-03-05 2011-06-09 Vegenics Pty Ltd Materialien und verfahren für wachstumsfaktorbindende konstrukte
MXPA06014015A (es) * 2004-06-03 2007-02-08 Hoffmann La Roche Tratamiento con gemcitabina y un inhibidor del receptor del factor de crecimiento epidermico.
US7691827B2 (en) 2004-12-17 2010-04-06 Eli Lilly And Company Amide prodrug of gemcitabine, compositions and use thereof
US20060216288A1 (en) * 2005-03-22 2006-09-28 Amgen Inc Combinations for the treatment of cancer
WO2008099908A1 (ja) 2007-02-16 2008-08-21 Oncotherapy Science, Inc. 脈絡膜新生血管のワクチン療法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060216301A1 (en) * 2002-09-12 2006-09-28 Oncotherapy Science, Inc. Kdr peptides and vaccines containing the same

Also Published As

Publication number Publication date
CA2697501A1 (en) 2009-03-05
TW200914037A (en) 2009-04-01
CN101883577A (zh) 2010-11-10
TWI436775B (zh) 2014-05-11
AU2008292966C1 (en) 2013-03-14
AU2008292966A1 (en) 2009-03-05
KR20100047899A (ko) 2010-05-10
UA100702C2 (ru) 2013-01-25
NZ583578A (en) 2012-07-27
SG183770A1 (en) 2012-09-27
RU2472522C2 (ru) 2013-01-20
EP2195003A1 (en) 2010-06-16
JP5417667B2 (ja) 2014-02-19
US8703713B2 (en) 2014-04-22
RU2010111139A (ru) 2011-09-27
ZA201001580B (en) 2011-02-23
IL204143A (en) 2013-04-30
AR068020A1 (es) 2009-10-28
MY160406A (en) 2017-03-15
MX2010002178A (es) 2010-03-18
US20110082088A1 (en) 2011-04-07
BRPI0815726A2 (pt) 2016-01-05
WO2009028150A1 (en) 2009-03-05
AU2008292966B2 (en) 2012-07-19
JP2010536714A (ja) 2010-12-02

Similar Documents

Publication Publication Date Title
ZA201001580B (en) Combination therapy for pancreatic cancer using an antigenic peptide and chemotherapeutic agent
IL195371A0 (en) Mobile radiation therapy
EP2146632A4 (en) COMPOSITIONS AND METHODS FOR CELLULAR IMAGE PRESENTATION AND THERAPY
EP2127671A4 (en) THERAPEUTIC AGENT AGAINST CANCER
EP2025347A4 (en) PROPHYLACTIC AND THERAPEUTIC AGENTS AGAINST CANCER
EP1967209A4 (en) THERAPEUTIC AGENT AGAINST PROSTATE CANCER
EP2506881A4 (en) COMBINATION OF RADIOIMMUNTHERAPY AND ANTIBODY ARZNEI CONJUGATES FOR IMPROVED CANCER THERAPY
EP2135600A4 (en) AGENT FOR TARGETING CANCER CELLS OR FIBROBLASTS ASSOCIATED WITH CANCER
IL197389A0 (en) Prophylactic or therapeutic agent for cancer
GB0519405D0 (en) Cancer therapy prognosis and target
IL178920A0 (en) Treatment for pancreatic cancer
HUE037109T2 (hu) Endoxifén rák kezelésében történõ alkalmazásra
EP1841467A4 (en) COMBINATION CANCER THERAPY WITH ANTI-PSMA ANTIBODIES
EP2010216A4 (en) MYCOBACTERIAL IMMUNOTHERAPY FOR CANCER TREATMENT
EP2148685A4 (en) METHODS AND COMPOUNDS FOR THERAPY BASED ON VITAMIN D
IL194826A0 (en) Compositions and methods for cellular imaging and therapy
EP2023950A4 (en) CANCER TREATMENT WITH URODILATIN
EP2090585A4 (en) ANTIGENIC POLYPEPTIDES THAT APPRECIATE AS THERAPEUTIC AGENTS AGAINST MALIGNE NEOPLASMS
EP2295598A4 (en) METHOD AND KIT FOR DETECTING CANCER, AND THERAPEUTIC AGENT FOR CANCER
EP2123266A4 (en) THERAPEUTIC AGENT AGAINST CANCER AND ANTI-CARCINOGENIC AGENT
EP2144887A4 (en) PHARMACEUTICAL FORMS AND METHOD FOR THE TREATMENT OF CANCER
HK1110224A1 (en) Therapeutic agent for cancer
IL199911A0 (en) 3-cinnolinecarboxamide derivatives and their use for treating cancer
EP2018873A4 (en) PROPHYLACTIC / THERAPEUTIC AGENT FOR CANCER
EP1871166A4 (en) VACCINES AGAINST CANCER AND THERAPEUTIC METHODS

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20100319

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA MK RS

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1140148

Country of ref document: HK

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20110609

17Q First examination report despatched

Effective date: 20120424

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20140620

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20141127

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20150408

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1140148

Country of ref document: HK